386 related articles for article (PubMed ID: 16365467)
1. Empirical anti-Candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysis.
Golan Y; Wolf MP; Pauker SG; Wong JB; Hadley S
Ann Intern Med; 2005 Dec; 143(12):857-69. PubMed ID: 16365467
[TBL] [Abstract][Full Text] [Related]
2. High- versus low-dose fluconazole therapy for empiric treatment of suspected invasive candidiasis among high-risk patients in the intensive care unit: a cost-effectiveness analysis.
Chen H; Suda KJ; Turpin RS; Pai MP; Bearden DT; Garey KW
Curr Med Res Opin; 2007 May; 23(5):1057-65. PubMed ID: 17519072
[TBL] [Abstract][Full Text] [Related]
3. De-escalation from micafungin is a cost-effective alternative to traditional escalation from fluconazole in the treatment of patients with systemic Candida infections.
Masterton RG; Casamayor M; Musingarimi P; van Engen A; Zinck R; Odufowora-Sita O; Odeyemi IA
J Med Econ; 2013 Nov; 16(11):1344-56. PubMed ID: 24003830
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation.
Zilberberg MD; Kothari S; Shorr AF
Crit Care; 2009; 13(3):R94. PubMed ID: 19545361
[TBL] [Abstract][Full Text] [Related]
5. Cost Effectiveness of Candida Polymerase Chain Reaction Detection and Empirical Antifungal Treatment among Patients with Suspected Fungal Peritonitis in the Intensive Care Unit.
Pagès A; Iriart X; Molinier L; Georges B; Berry A; Massip P; Juillard-Condat B
Value Health; 2017 Dec; 20(10):1319-1328. PubMed ID: 29241891
[TBL] [Abstract][Full Text] [Related]
6. Caspofungin versus amphotericin B for candidemia: a pharmacoeconomic analysis.
Wingard JR; Wood CA; Sullivan E; Berger ML; Gerth WC; Mansley EC
Clin Ther; 2005 Jun; 27(6):960-9. PubMed ID: 16117996
[TBL] [Abstract][Full Text] [Related]
7. Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species.
Ou HT; Lee TY; Chen YC; Charbonneau C
BMC Infect Dis; 2017 Jul; 17(1):481. PubMed ID: 28693479
[TBL] [Abstract][Full Text] [Related]
8. Seven-year trend analysis of nosocomial candidemia and antifungal (fluconazole and caspofungin) use in Intensive Care Units at a Brazilian University Hospital.
Girão E; Levin AS; Basso M; Gobara S; Gomes LB; Medeiros EA; Costa SF
Med Mycol; 2008 Sep; 46(6):581-8. PubMed ID: 19180727
[TBL] [Abstract][Full Text] [Related]
9. Caspofungin versus amphotericin B for invasive candidiasis.
Brown AL; Greig JR
N Engl J Med; 2003 Mar; 348(13):1287-8; author reply 1287-8. PubMed ID: 12660396
[No Abstract] [Full Text] [Related]
10. Caspofungin therapy of neonates with invasive candidiasis.
Odio CM; Araya R; Pinto LE; Castro CE; Vasquez S; Alfaro B; Sàenz A; Herrera ML; Walsh TJ
Pediatr Infect Dis J; 2004 Dec; 23(12):1093-7. PubMed ID: 15626944
[TBL] [Abstract][Full Text] [Related]
11. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study.
Kett DH; Azoulay E; Echeverria PM; Vincent JL;
Crit Care Med; 2011 Apr; 39(4):665-70. PubMed ID: 21169817
[TBL] [Abstract][Full Text] [Related]
12. Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever.
Wingard JR; Leather HL; Wood CA; Gerth WC; Lupinacci RJ; Berger ML; Mansley EC
Am J Health Syst Pharm; 2007 Mar; 64(6):637-43. PubMed ID: 17353573
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of Candida krusei infection with caspofungin acetate: a new antifungal agent.
McGee WT; Tereso GJ
Crit Care Med; 2003 May; 31(5):1577-8. PubMed ID: 12771636
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis.
Auzinger G; Playford EG; Graham CN; Knox HN; Weinstein D; Kantecki M; Schlamm H; Charbonneau C
BMC Infect Dis; 2015 Oct; 15():463. PubMed ID: 26503366
[TBL] [Abstract][Full Text] [Related]
15. Comparison of caspofungin and amphotericin B for invasive candidiasis.
Mora-Duarte J; Betts R; Rotstein C; Colombo AL; Thompson-Moya L; Smietana J; Lupinacci R; Sable C; Kartsonis N; Perfect J;
N Engl J Med; 2002 Dec; 347(25):2020-9. PubMed ID: 12490683
[TBL] [Abstract][Full Text] [Related]
16. Caspofungin: a review of its use in the treatment of fungal infections.
McCormack PL; Perry CM
Drugs; 2005; 65(14):2049-68. PubMed ID: 16162025
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole.
Kartsonis N; DiNubile MJ; Bartizal K; Hicks PS; Ryan D; Sable CA
J Acquir Immune Defic Syndr; 2002 Oct; 31(2):183-7. PubMed ID: 12394797
[TBL] [Abstract][Full Text] [Related]
18. Management of systemic candidal infections in the intensive care unit.
Kam LW; Lin JD
Am J Health Syst Pharm; 2002 Jan; 59(1):33-41. PubMed ID: 11813465
[TBL] [Abstract][Full Text] [Related]
19. Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis.
Keating G; Figgitt D
Drugs; 2003; 63(20):2235-63. PubMed ID: 14498760
[TBL] [Abstract][Full Text] [Related]
20. Cost-utility analysis of caspofungin and fluconazole for primary treatment of invasive candidiasis and candidemia in Ethiopia.
Gebretekle GB; Fentie AM; Gebremariam GT; Ali EE; Erku DA; Alemayehu T; Abebe W; Sander B
BMC Health Serv Res; 2022 Oct; 22(1):1302. PubMed ID: 36309674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
